The growth-hormone peptide market: 995 storefronts checked
A 995-storefront census found tesamorelin on 714 stores at a $79 median per 10 mg, with 6.54% modeled share, $282M modeled revenue and 416% search growth.
Peptide guides, price comparisons & research
Beginner-friendly guides grounded in peer-reviewed research. Compare prices, understand the science, and research smarter.
Browse testing lab reviews and official COA verification guides →GLP-3R Phase 3 Results: What TRIUMPH-1 Shows — and What It Doesn't
GLP-3R Phase 3 results from TRIUMPH-1: 25.0% mean weight loss at 80 weeks on 12 mg vs 3.9% placebo, plus knee pain, sleep apnea, safety data, and the
Trevogrumab + GLP-1S (COURAGE): What the 52-Week Muscle-Preservation Data Show
Regeneron's Oct 1 COURAGE release: trevogrumab cut GLP-1S lean-mass loss to 4.2% vs 7.3% at 52 weeks. Phase 2, antibody, not approved. What it shows.
EloraTZP Phase 2 Results: 23.3% Weight Loss With Eloralintide + GLP-2T in T2D
Phase 2b data from EASD 2026: EloraTZP hit 23.3% mean weight loss at 48 weeks in T2D adults vs 14.8% on GLP-2T alone. Key numbers, tolerability, and what comes
How to read a peptide certificate of analysis: the core three-panel test and extended testing
Read peptide COAs with identity, purity, content and extended-panel examples. Includes PeptidePrices report counts, lab coverage and issuer verification.
The core three-panel COA test: identity, purity and measured content
Understand the core three-panel peptide COA test: LC-MS or retention-time identity, HPLC-UV purity and measured content, with verified vendor examples.
Endotoxin testing on peptide COAs: what the LAL result means
Learn what LAL endotoxin results, EU units, reporting limits and controls mean on peptide COAs, with documented testing examples from eight vendors.
Sterility and microbial testing on peptide COAs
Compare USP 71 sterility testing with PCR microbial screens on peptide COAs. Read methods, sample scope and verified vendor archive examples.
Heavy-metal testing on peptide COAs (ICP-MS)
Read ICP-MS heavy-metal panels on peptide COAs: elements, units, detection limits and ICH Q3D context, with verified vendor archive examples.
Amino Club vs NeuroLabs: Prices, COAs, Coupons & Verdict
Amino Club vs NeuroLabs: 10/10 vs 8.5/10 evidence scores, 25 shared compounds priced side by side, verified COA counts, labs, coupons, shipping, and a use-case verdict.
Amino Club vs BioLongevity Labs: Prices, COAs, Coupons & Verdict
Amino Club vs BioLongevity Labs: 10/10 vs 8/10 evidence scores, 19 shared compounds priced side by side, verified COA counts, labs, coupons, shipping, and a use-case verdict.
NeuroLabs vs BioLongevity Labs: Prices, COAs, Coupons & Verdict
NeuroLabs vs BioLongevity Labs: 8.5/10 vs 8/10 evidence scores, 16 shared compounds priced side by side, verified COA counts, labs, coupons, shipping, and a use-case verdict.
Ameano Peptides vs Orbitrex Peptides: Prices, COAs, Coupons & Verdict
Ameano Peptides vs Orbitrex Peptides: 9.5/10 vs 9.5/10 evidence scores, 30 shared compounds priced side by side, verified COA counts, labs, coupons, shipping, and a use-case verdict.
EZ Peptides vs PS Peptides: Prices, COAs, Coupons & Verdict
EZ Peptides vs PS Peptides: 9/10 vs 9/10 evidence scores, 16 shared compounds priced side by side, verified COA counts, labs, coupons, shipping, and a use-case verdict.
CagriSema REIMAGINE 5 vs GLP-2T: Phase 3 Head-to-Head Results
Novo's CagriSema 1.0/1.0 mg outperformed GLP-2T 5 mg (12.4% vs 9.1% weight loss) in REIMAGINE 5. FDA decision expected Q4 2026. Here's what the dose gap means.
1.1 Million US Adults Had GLP-1 Prescriptions Without an Apparent Approved Indication, Study Finds
Study in Obesity: 1.1 million US adults had GLP-1 prescriptions without an apparent FDA-approved indication, 2021-2025. Rate rose 15-fold.
Orbis and Novo Sign Up to $1.4B Oral Macrocycle Deal: Discovery Pact, Not a Peptide Approval
Orbis and Novo announced a up-to-$1.4B oral macrocycle discovery pact for cardiometabolic disease on Sept. 17, 2026. Discovery deal, not clinical data or FDA approval.
SYNT-101 Phase 1 MAD: Oral Gut Lining Raises Endogenous GLP-1 and PYY, Not a Peptide Approval
Syntis Bio said 28-day SYNT-101 MAD (n=23) raised endogenous GLP-1 and PYY 2- to 5-fold. Oral gut lining, not a peptide drug. No published weight-loss percent.
FDA Approves ISEMBYLD (Apitegromab): First Muscle-Targeted SMA Therapy, Not a Research Peptide
FDA approved ISEMBYLD (apitegromab-mstn) on Sept. 11, 2026, as an SMA add-on for patients 2+ on SMN2 therapy. SAPPHIRE: +2.2 HFMSE. Not a research peptide.
Navepegritide reACHin Infant Data: Foramen Magnum Stable or Improved at Week 52, Not Infant Label
ESPE 2026 n=7 open-label reACHin infants: AFMS stable or improved, no decompression. Sentinel data, not infant FDA approval and not the blinded RCT.
Pep19 Oral Peptide: Fat Redistribution Without Weight Loss in iScience RCT, Not an Incretin Approval
iScience RCT: 10 mg Pep19 shifted android-to-gynoid fat vs placebo without meaningful weight loss. Not a GLP-1. Not FDA-approved for obesity.
GZC8072 Once-Weekly Oral Peptide GLP-1 Starts Phase 1: First Dose, Not Efficacy
Gan & Lee dosed the first participant in a China Phase 1 of GZC8072, a once-weekly oral peptide GLP-1. First dose is not efficacy or approval.
Vosoritide CANOPY-HCH-3: +2.33 cm/year AGV in Hypochondroplasia, Not an FDA Approval
CANOPY-HCH-3: vosoritide LSM AGV +2.33 cm/year vs placebo in 81 children with hypochondroplasia. NEJM Evidence plus HCH sNDA. Not an FDA approval.
Redasemtide Phase 2: DEB Ulcer Closure in 3 of 4, Stroke mRS Miss, Not Approval
Shionogi said redasemtide closed refractory DEB ulcers in 3 of 4. Global Phase 2b stroke missed Day-90 mRS versus placebo. Investigational, not approval.
STEP Young GLP-1S Phase 3: 40.4% of Children 6 to Under 12 Below Obesity, Not FDA Approval
Novo Nordisk said STEP Young met its week-68 BMI endpoint in 165 children aged 6 to under 12. 40.4% left the obesity class versus 0% placebo. Not an FDA approval.
FDA Approves Rusfertide (Mimrylo): Hepcidin Mimetic for Polycythemia Vera, Not a Weight-Loss GLP-1
FDA approved Mimrylo (rusfertide) on Aug. 28, 2026, for erythrocytosis in adults with polycythemia vera. VERIFY: 76.9% vs 32.9% response. Not a weight-loss GLP-1.
TT-P34 Phase I: Parkinson's Peptide Clears First Human Safety Bar, Not Disease Modification
Teitur reported Phase I safety, weekly SC brain exposure, and CSF lysosomal trends for TT-P34 on Sept. 10, 2026. Not efficacy or FDA approval.
AZD5462 LUMINARA: Oral RXFP1 Agonist Phase 2b in Heart Failure, Not an Outcomes Win
LUMINARA tested oral AZD5462, a small-molecule RXFP1 agonist, in Phase 2b heart failure. Cohort A ESVi P=0.054. Not an outcomes win or FDA approval.
ASC36 Oral Amylin Peptide Starts U.S. Phase 1: What Ascletis Still Must Prove
Ascletis started a U.S. Phase I study of oral ASC36, an amylin receptor peptide, on Sept. 8, 2026. Start is not efficacy. Company NHP figures are animal data.
Dihexa Peptide Evidence: Preclinical Cognition Claims, Retracted Mechanism Paper, Not Human Efficacy
Dihexa is an Ang IV analog. Independent APP/PS1 mice improved maze scores. The HGF papers were retracted. That is not human efficacy.
Pinealon (EDR) Peptide Evidence: Preclinical Neuroprotection, Not Human Efficacy
Pinealon is a synthetic Glu-Asp-Arg tripeptide. Cell and rodent papers show ROS and maze changes. That is not human efficacy or an approved dose.
SLU-PP-332 ERR Agonist Evidence: Preclinical Exercise Mimetic, Not Human Efficacy
SLU-PP-332 is a small-molecule ERR agonist, not a peptide. Mouse papers show endurance and fat-mass changes. That is not human efficacy or an approved dose.
Humanin Peptide Evidence: Preclinical Neuroprotection and Metabolism, Not Human Efficacy
Humanin is a mitochondrial-derived peptide. Cell and rodent papers show neuroprotection. Human data are circulating associations, not efficacy or an approved dose.
Survodutide Phase 3 SYNCHRONIZE: 16.6% Weight Loss, Visceral and Liver Fat Cuts, Not FDA Approved
Survodutide Phase 3 SYNCHRONIZE-1 showed up to 16.6% weight loss at 76 weeks. MASLD trial cut liver fat. Investigational, not FDA-approved. No NDA announced.
NAD+ IV Infusion Evidence: Human Metabolome Changes, Not Longevity Efficacy
NAD+ is a dinucleotide, not a peptide. A 2019 pilot infused 750 mg IV over 6 hours. Plasma NAD+ rose after 2 hours. That is not longevity proof or an approved dose.
FOXO4-DRI Senolytic Evidence: Preclinical Studies, Not Human Efficacy
FOXO4-DRI is a senolytic peptide studied in cells and mice, not people. Cell 2017 and later independent papers show a mechanism, not human efficacy or a dose.
Pemvidutide PERFORMA Phase 3 Starts in MASH: What Altimmune Still Must Prove
Altimmune began enrolling PERFORMA on August 3, 2026, a Phase 3 MASH trial of pemvidutide. Start is not efficacy. IMPACT 48-week NITs are not histology.
What Is MariTide (Maridebart Cafraglutide)? Monthly Peptide-Antibody Conjugate and Phase 2 Evidence
MariTide is Amgen's monthly GLP-1 agonist and GIP antagonist conjugate. Phase 2 ITT weight loss was 12.3 to 16.2 percent. Phase 3 is unfinished.
VK2735 Phase 3 VANQUISH Fully Enrolled: What Viking's Dual GLP-1/GIP Peptide Still Must Prove
Viking said VANQUISH-1 and VANQUISH-2 are fully enrolled. Phase 2 VENTURE showed up to 14.7% weight loss at 13 weeks. Phase 3 efficacy is still unproven.
Avexitide Phase 3 LUCIDITY: GLP-1 Antagonist Cuts Severe Hypoglycemia After Gastric Bypass
Amylyx LUCIDITY: avexitide, a GLP-1 antagonist, cut Level 2+3 hypoglycemia 55% vs placebo after RYGB (p=0.000003). Topline Phase 3, not FDA approval.
ASC30 Starts Phase 3: What the Oral GLP-1 Trial Will Test
Ascletis dosed the first AURORA Phase 3 participant for oral small-molecule GLP-1 ASC30. What the 72-week trials will test, and what 13-week Phase 2 showed.
FDA Approves Mounjaro for Cardiovascular Risk in Type 2 Diabetes
FDA approved Mounjaro to reduce MACE in high-risk type 2 diabetes. SURPASS-CVOT was noninferior to Trulicity. Superiority was not established.
Mazdutide Phase 2 Results: 18.1% Weight Loss at 32 Weeks
Mazdutide's US Phase 2 showed up to 18.1% weight loss at 32 weeks — but 20% discontinued the top dose. The dose–tolerability tradeoff, with 48-week data, explained.
HM17321 UCN2 Analog: Genentech's $2.3B Non-Incretin Obesity Bet, Explained
Genentech licensed Hanmi's HM17321, a UCN2 analog peptide, for up to $2.3B before any human efficacy data. What UCN2 signaling is and what still must be proven.
BPC-157 for Dogs: Evidence, Dosing and What Owners Should Know
Does BPC-157 work for dogs? Review beagle bioavailability, published canine doses, safety data, veterinary cases and where products are sold.
GLP-3R Interest Is Surging: The Timeline to Lilly's Planned 2027 FDA Submission
Is GLP-3R FDA approved? Not yet. Follow Lilly's planned Q1 2027 submission timeline and the rise in search, testing and internal interest.
FDA Warned 13 Research-Peptide Sellers. Ten Are Still Selling Peptides.
PeptidePrices reviewed 13 FDA research-peptide warning letters. Ten warned businesses still sell peptides through public or account-gated storefronts.
ARA-290 Peptide Dosage: Human Trial Doses, Nerve Repair, and Pricing
ARA-290 human trials tested 2 mg IV and 1, 4, or 8 mg SC. See why 4 mg stood out, the nerve-repair evidence, FDA status, and live pricing.
DSIP Peptide: Why FDA Advisers Voted Against It
FDA advisers voted against adding DSIP peptide forms to the 503A Bulks List. See the vote, evidence gaps, and what the decision does not mean.
PCAC Recommends BPC-157, KPV, TB-500, and MOTS-c for 503A Compounding
FDA's PCAC voted 8-6-1 to recommend BPC-157, KPV, TB-500, and MOTS-c for the 503A Bulks List. Learn what the advisory votes do and do not change.
KLOW Peptide Blend: Ingredients, Evidence, and Risks
KLOW combines GHK-Cu, BPC-157, TB-500, and KPV. Review what each ingredient is, what human studies show, and what the full blend has not proved.
GLP-1 Microdosing: Evidence, Risks, and Real Cost
What does GLP-1 microdosing mean? Review the evidence, FDA-approved dose schedules, compounded-drug risks, advertised costs, and provider checks.
GHK-Cu for Skin, Hair, and Injections: Human Evidence
Does GHK-Cu help skin or hair? Compare human, animal, and laboratory evidence for topical copper peptides, hair claims, and injectable GHK-Cu.
Peptides for Women's Weight Loss: Evidence in 2026
Which weight-loss peptides have real evidence for women? Compare GLP-1S, GLP-2T, compounded options, safety, and telehealth access.
Peptides for Women Over 40: Evidence and Red Flags
An evidence-first guide to peptides for women over 40: weight management, skin, recovery, sexual health, menopause limits, and safety red flags.
Introducing the PeptidePrices Chrome Extension: Automatic Partner Coupons at Checkout
Our free Chrome extension auto-applies PeptidePrices partner-vendor coupon codes at checkout, so you never miss a discount. No copy-pasting, no personal-data collection. Here is exactly what it does, how it works, and how to install it.
What Centenarians' Immune Systems Reveal About Longevity (and Where Research Peptides Actually Fit)
A 2026 Nature Reviews Immunology review maps how people who reach 100+ stay biologically young: lower NLRP3 inflammation, more autophagy, calmer cellular senescence, an intact gut barrier. The honest science, and where the longevity compounds people research fit, and don't.
BGE-102 and the Inflammaging Bet: An Oral NLRP3 Inhibitor Cut hsCRP ~85% in a Phase 1 Trial
BioAge's BGE-102, an oral NLRP3 inhibitor, drove ≥85% median hsCRP reductions in a Phase 1 obesity cohort. The honest read — the data, the CANTOS precedent, the crowded NLRP3 race, and what it means (and doesn't) for inflammaging.
The Gene Switch for Regeneration: How ALDH1A2 and Retinoic Acid Made Mice Regrow Lost Tissue
In a 2025 Science study, scientists restored regenerative wound healing in mice by switching ALDH1A2 back on — the enzyme that makes retinoic acid. Here's the honest science, plenty of sources, and what it does (and doesn't) mean for healing.
AI Is Designing Drugs Now: Insilico Medicine, AlphaFold, and the Honest State of AI in Peptide Design
A generative-AI-designed drug just published Phase 2a human data in Nature Medicine. Here's the honest breakdown of Insilico Medicine's rentosertib, what AlphaFold actually changed, how AI is being used to design new peptides — and why your GLP-1S was not AI-designed.
How to verify a peptide COA
How to verify a peptide COA: named lab, batch match, and lab-portal lookup. Use the free /coa-check tool. Not medical advice.
The One-Shot Gene Therapy That Wants to Replace Weekly GLP-1S: Fractyl's Rejuva, Explained
Fractyl's Rejuva (RJVA-001) is an experimental AAV gene therapy designed to make your own pancreas produce GLP-1 — a potential one-time alternative to weekly GLP-1S. The mechanism, the preclinical data, the May 2026 first-in-human authorization, and the honest caveats about a treatment you can't undo.
Peptide Fulfillment for Research Brands: Our RapidFulfillment Partnership
RapidFulfillment is PeptidePrices' fulfillment and cold-chain logistics partner for research peptide brands — RUO peptide fulfillment, white-label dropshipping, and cold-chain logistics. Mention PeptidePrices for $300 off your fulfillment deposit.
RLS-1496, Explained: A First-in-Class GPX4 Cream That Targets 'Senescent' Skin Cells
RLS-1496 is Rubedo Life Sciences' first-in-class topical GPX4 modulator — a cream designed to clear senescent 'zombie' skin cells via ferroptosis. The Phase 1 and Phase 1b/2a data across psoriasis, atopic dermatitis, photoaging and actinic keratosis (a company-reported 46% lesion drop in 4 weeks), the 'senoadaptive' thesis, and the honest caveats.
The One-Time Shot That Edits Your DNA to Lower Cholesterol: VERVE-102, Explained
VERVE-102 is a single-infusion gene-editing therapy that permanently switches off the PCSK9 gene to lower LDL cholesterol. The Heart-2 trial data, the VERVE-101 safety scare, the $1.3B Lilly buyout, and the honest caveats about a treatment you can't undo.
What the GLP-1 Pipeline Showed at ADA 2026: GLP-3R, CagriSema, Orforglipron
The ADA's 86th Scientific Sessions (June 5–8, 2026) dumped the year's biggest GLP-1 data: GLP-3R's ~28% weight loss, CagriSema's first diabetes trials, and orforglipron's oral readout. A plain-English roundup — including the caveats.
BPC-157's Human-Evidence Problem: What the Trials Actually Show
BPC-157 has a huge, impressive animal-research literature and almost no human-trial data. Both are true. Here's exactly what's been published in people — the PL-14736 program, the registered-but-unpublished trial — and why the gap matters.
SS-31 (Elamipretide): The Mitochondrial Peptide That Just Became an FDA Drug
On Sept 19, 2025, SS-31 became FORZINITY — the first FDA-approved drug to directly target the mitochondria. But the approval is for an ultra-rare disease, and the broad anti-aging story is messier than the headline. What the cardiolipin-binding peptide actually does, and doesn't.
GLP-1s Are Becoming "Everything" Drugs: The New Indications Beyond Weight Loss
GLP-1s are no longer just diabetes and weight-loss drugs. A clear-eyed map of what's actually FDA-approved (heart, sleep apnea, MASH), what has strong trial data (kidney), and what has failed or is still hype (Alzheimer's, addiction).
The Cholesterol Pill That's Secretly a Peptide: Enlicitide, Explained
Enlicitide (Merck's former MK-0616) is a once-daily cholesterol pill that's really an oral macrocyclic peptide — engineered to survive the gut. The Phase 3 CORALreef data, the empty-stomach catch, and what it signals for oral peptide drugs.
The FDA's July 2026 Peptide Hearing: What's Actually on the Table
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviews 7 peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) for the 503A compounding list, with 5 more by early 2027. Here's what the hearing means, and what it doesn't.
Orforglipron Brand Name: Foundayo, FDA Approval and How It Works
Orforglipron's U.S. brand name is Foundayo. The FDA approved it on April 1, 2026. Read about the oral GLP-1, trial results and injectable comparisons.
What the Peptide Skeptics Agree On: Topol, Attia & Saladino
Three credible voices, cardiologist Eric Topol, Peter Attia, and Paul Saladino, have pushed back on the peptide boom. Here's where they actually converge: the human-trial evidence gap, the GLP-1 exception, and the gray-market quality problem.
Dr. Paul Saladino's Peptide Breakdown: "No Biological Free Lunch"
Dr. Paul Saladino's YouTube breakdown of peptides, GLP-1s, BPC-157/TB-500, GH secretagogues, melanotan, sorted into what's effective, what's risky, and why he argues there's no biological free lunch. We separate his verifiable points from his strong opinions.
Huberman's Peptide Episode with Dr. Abud Bakri: The Full Breakdown
A clear, fact-checked breakdown of the Huberman Lab peptides episode with Dr. Abud Bakri — BPC-157, GLP-1s, the Russian bioregulators, the thymus, GH secretagogues, and the gray-market reality. We separate the established science from the anecdotes.
Drug or Biologic? The Lilly–FDA Fight Over GLP-3R, Explained
Eli Lilly is fighting the FDA over whether GLP-3R is a small-molecule drug or a biologic, a distinction that turns on amino-acid counting and could reshape competition, compounding, and the obesity-drug market. Here's what's actually at stake.
Best Peptides for Joint Pain, Tendons, and Ligaments (2026)
Looking at peptides for joint pain or tendon recovery? We rank the 7 most-researched options by evidence quality, side-effect profile, and current 2026 vendor pricing.
How to Vet a Peptide Vendor: A Buyer's Checklist
Six concrete criteria for checking whether a peptide vendor is trustworthy — named labs, batch COAs, endotoxin, address, track record, reviews.